Introduction {#Sec1}
============

It is widely accepted that the accumulation of genetic and epigenetic alterations contributes to cancer initiation and progression. Genetic alterations refer to mutations in tumor suppressor genes and oncogenes, whereas epigenetic modifications involve changes in chromatin structure that result in altered gene expression without primary changes to the DNA sequence \[[@CR1]\]. The information conveyed by epigenetic modifications plays a vital role in regulating DNA-mediated processes, including transcription, DNA repair, and replication \[[@CR2]\]. Specifically, aberrant DNA methylation at the 5-carbon on cytosine residues (5mC) in CpG dinucleotides is perhaps the most extensively characterized epigenetic modification in cancer. DNA methylation affects the rate of gene transcription and therefore regulates various biological processes, such as proliferation, apoptosis, DNA repair, cancer initiation, and cancer progression \[[@CR3]\]. The genomic DNA methylation pattern is stably maintained in normal cells; however, aberrant alterations in the epigenome have been identified in tumor cells \[[@CR4]\]. Evidence suggests that global hypomethylation and regional hypermethylation are characteristics of cancer cells \[[@CR5]\]. Global genome-wide loss of methylation has been associated with increased genomic instability and proto-oncogene activation, whereas DNA hypermethylation of CpG islands in promoter regions silences tumor suppressor genes \[[@CR6]\]. Unlike genetic mutations, the transcriptional repression of genes via epigenetic alterations can be reversed by further epigenetic modifications because these silenced genes remain genetically intact \[[@CR7]\]. Thus, it is very important to profile the global DNA methylation changes that occur in early tumorigenesis.

Colorectal cancer (CRC) is the second leading cause of cancer-related death in western countries \[[@CR8]\], and more than 80 % of CRC patients harbor a mutation in the adenomatous polyposis coli (APC) gene on chromosome 5q21 \[[@CR9]\]. APC is a tumor suppressor gene that down-regulates the pro-proliferative Wnt-signaling pathway by promoting the destruction of β-catenin. Deleterious mutations in APC stabilize β-catenin, increase its translocation into the nucleus, promote its binding to the transcription factor TCF4, and activate target genes such as C-MYC and CCND1 \[[@CR10], [@CR11]\]. It has been suggested that the loss of APC function initiates tumorigenesis and that additional genetic and epigenetic events are involved in colon cancer progression \[[@CR12]\]. Numerous genes that are silenced by epigenetic mechanisms have been identified in colon cancer, including CDKN2A \[[@CR13]\], DKK1 \[[@CR14]\], DLEC1 \[[@CR15], [@CR16]\], UNC5C \[[@CR17]\], and SFRP \[[@CR18]\]. However, the genome-wide profile of the aberrant methylation and the association of these methylation patterns with important signaling pathways and biological networks implicated in colon tumorigenesis remain unclear.

To address this issue, we examined the global DNA methylation profile in the well-established Apc^min/+^ intestinal tumorigenesis mouse model using methylated DNA immunoprecipitation (MeDIP) and next-generation sequencing (MeDIP-seq). Apc^min/+^ mice carry a heterozygous mutation in Apc and develop approximately 30 small intestinal adenomatous polyps following the somatic loss of functional Apc \[[@CR19]\]. This mouse model of intestinal tumorigenesis is commonly used because the phenotype resembles that of patients with familial adenomatous polyposis (FAP) \[[@CR20]\]. We analyzed adenomatous polyps from Apc^min/+^ mice and not only identified genes with a modified methylation profile but also interpreted the data in the context of biological function, networks, and canonical signaling pathways associated with the methylation patterns.

Results {#Sec2}
=======

MeDIP-seq results {#Sec3}
-----------------

To identify changes in DNA methylation patterns during the progression of mouse intestinal polyps, whole-genome DNA methylation analysis was performed using the described MeDIP-seq method. The global differences in the DNA methylation profile between adenomatous polyps from Apc^min/+^ mice and intestinal tissue from control mice are described in Fig. [1](#Fig1){ref-type="fig"}. We identified 12,761,009 mapped peaks and 2,868,549 non-mapped peaks from a total of 15,629,558 peaks in control mice and 11,470,541 mapped peaks and 2,262,073 non-mapped peaks from a total of 13,732,614 peaks in Apc^min/+^ mice (Fig. [1a](#Fig1){ref-type="fig"}). A total of 17,265 differentially methylated regions (DMRs) had a ≥ 2-fold change (log~2~) in methylation in Apc^min/+^ mice compared with control mice, of which 9,078 DMRs (52.6 %) exhibited increased methylation, and 8,187 (47.4 %) DMRs exhibited decreased methylation (Fig. [1b](#Fig1){ref-type="fig"}).Fig. 1Global changes in the DNA methylation profile between Apc mutant adenomatous polyps and control tissue. **a**, Total number of peaks generated by MeDIP-seq. **b**, Number of DMRs with significantly increased or decreased changes in methylation (≥2-fold in log~2~) in polyps from Apc^min/+^ mice

Functional and pathway analysis by IPA {#Sec4}
--------------------------------------

To identify the biological function, networks, and canonical pathways that were affected by the differentially methylated genes, we performed Ingenuity Pathway Analysis (IPA) after the MeDIP-seq analysis. In the analysis of genes with altered methylation (≥2-fold in log~2~) in Apc^min/+^ mice compared with control mice as determined by MeDIP-seq, IPA mapped 5,464 unique genes that were associated with its knowledge base. The top 50 genes with increased and decreased methylation levels based on log~2~ fold change are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. The molecules with methylation changes were mainly categorized into 38 disease and biological functions. The five highest IPA-rated disease and biological functions were as follows: cancer, gastrointestinal disease, organismal injury and abnormalities, cellular growth and proliferation, and reproductive system disease (Fig. [2](#Fig2){ref-type="fig"}). Among the IPA-mapped genes with differential methylation patterns in polyps from Apc^min/+^ mice, 3,299 were associated with cancer, and 1,668 were associated with gastrointestinal diseases. To examine the interaction networks that were affected by DNA methylation in Apc mutant polyps, IPA identified 25 networks with up to 35 focus molecules in each network. The five most affected gene networks as determined by IPA are shown in Table [3](#Tab3){ref-type="table"}, and the detailed interactions in the most significant networks (cancer, cell cycle, and molecular transport) are presented in Fig. [3](#Fig3){ref-type="fig"}. In accordance with the most relevant biological functions as determined by IPA, genes with different methylation patterns predominantly mapped to the networks associated with cancer and gastrointestinal diseases. Taken together, these results suggested an important role for the altered methylation of genes associated with the development of cancer and gut disease in Apc^min/+^ mice.Table 1Top 50 annotated genes with increased methylationRankSymbolGene namelog~2~ Fold ChangeLocationType(s)1ZNF330zinc finger protein 3304.614Nucleusother2ACTR3BARP3 actin-related protein 3 homolog B (yeast)4.540Otherother3CAV3caveolin 34.292Plasma Membraneenzyme4NKX2-3NK2 homeobox 34.199Nucleustranscription regulator5TLN2talin 24.199Nucleusother6CPDcarboxypeptidase D4.100Extracellular Spacepeptidase7CTNNBL1catenin, beta like 14.100Nucleusother8Vmn2r1vomeronasal 2, receptor 14.100Plasma Membraneother9Cmtm2aCKLF-like MARVEL transmembrane domain containing 2A3.993Cytoplasmtranscription regulator10HPS6Hermansky-Pudlak syndrome 63.993Cytoplasmother11KANK1KN motif and ankyrin repeat domains 13.993Nucleustranscription regulator12RRP1ribosomal RNA processing 13.993Nucleusother13SNX10sorting nexin 103.993Cytoplasmtransporter14UNC93Aunc-93 homolog A (C. elegans)3.993Plasma Membraneother15Zfp932zinc finger protein 9323.993Nucleusother16ANKRD13Dankyrin repeat domain 13 family, member D3.877Plasma Membraneother17DACT1dishevelled-binding antagonist of beta-catenin 13.877Cytoplasmother18DMRT2doublesex and mab-3 related transcription factor 23.877Nucleusother19DSC3desmocollin 33.877Plasma Membraneother20LDOC1leucine zipper, down-regulated in cancer 13.877Nucleusother21LRRC8Bleucine rich repeat containing 8 family, member B3.877Otherother22SEPP1selenoprotein P, plasma, 13.877Extracellular Spaceother23SMAD3SMAD family member 33.877Nucleustranscription regulator24Smok2asperm motility kinase 2B3.877Otherother25TCEAL3transcription elongation factor A (SII)-like 33.877Otherother26TNS1tensin 13.877Plasma Membraneother27TRHRthyrotropin-releasing hormone receptor3.877Plasma MembraneG-protein coupled receptor28WWC1WW and C2 domain containing 13.877Cytoplasmtranscription regulator29PER2period circadian clock 23.853Nucleusother30BHLHE23basic helix-loop-helix family, member e233.752Nucleustranscription regulator31GALNT13UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13)3.752Cytoplasmenzyme32KCNF1potassium voltage-gated channel, subfamily F, member 13.752Plasma Membraneion channel33MPP1membrane protein, palmitoylated 1, 55 kDa3.752Plasma Membranekinase34OPA1optic atrophy 1 (autosomal dominant)3.752Cytoplasmenzyme35PTP4A1protein tyrosine phosphatase type IVA, member 13.752Cytoplasmphosphatase36SGCZsarcoglycan, zeta3.752Plasma Membraneother37ADCY7adenylate cyclase 73.614Plasma Membraneenzyme38ALCAMactivated leukocyte cell adhesion molecule3.614Plasma Membraneother39ARandrogen receptor3.614Nucleusligand-dependent nuclear receptor40C4orf33chromosome 4 open reading frame 333.614Otherother41CCNHcyclin H3.614Nucleustranscription regulator42CDKN1Acyclin-dependent kinase inhibitor 1A (p21, Cip1)3.614Nucleuskinase43CDV3CDV3 homolog (mouse)3.614Cytoplasmother44COMTcatechol-O-methyltransferase3.614Cytoplasmenzyme45CRYGCcrystallin, gamma C3.614Cytoplasmother46FAM13Afamily with sequence similarity 13, member A3.614Cytoplasmother47IGF1Rinsulin-like growth factor 1 receptor3.614Plasma Membranetransmembrane receptor48IYDiodotyrosine deiodinase3.614Plasma Membraneenzyme49JAG1jagged 13.614Extracellular Spacegrowth factor50KCNMA1potassium large conductance calcium-activated channel, subfamily M, alpha member 13.614Plasma Membraneion channelTable 2Top 50 annotated genes with decreased methylationRankSymbolGene namelog~2~ Fold ChangeLocationType(s)1IRX1iroquois homeobox 1−5.897Nucleustranscription regulator2OSBP2oxysterol binding protein 2−5.408Cytoplasmother3CAPN5calpain 5−5.231Cytoplasmpeptidase4INTS9integrator complex subunit 9−4.837Nucleusother5TRIML1tripartite motif family-like 1−4.837Otherother6CSMD1CUB and Sushi multiple domains 1−4.614Plasma Membraneother7NCOR2nuclear receptor corepressor 2−4.272Nucleustranscription regulator8C6orf89chromosome 6 open reading frame 89−4.167Otherother9TMEM242transmembrane protein 242−4.167Otherother10DCLRE1ADNA cross-link repair 1A−4.100Nucleusother11EDNRAendothelin receptor type A−3.877Plasma Membranetransmembrane receptor12GALNT11UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 11 (GalNAc-T11)−3.877Cytoplasmenzyme13PTPN11protein tyrosine phosphatase, non-receptor type 11−3.877Cytoplasmphosphatase14AGPAT91-acylglycerol-3-phosphate O-acyltransferase 9−3.795Cytoplasmenzyme15IER5immediate early response 5−3.795Otherother16PPM1Dprotein phosphatase, Mg2+/Mn2+ dependent, 1D−3.708Cytoplasmphosphatase17RBBP6retinoblastoma binding protein 6−3.708Nucleusenzyme18BLOC1S2biogenesis of lysosomal organelles complex-1, subunit 2−3.614Cytoplasmother19CPEB2cytoplasmic polyadenylation element binding protein 2−3.614Cytoplasmother20ECI2enoyl-CoA delta isomerase 2−3.614Cytoplasmenzyme21MMGT1membrane magnesium transporter 1−3.614Cytoplasmtransporter22NALCNsodium leak channel, non-selective−3.614Plasma Membraneion channel23RETNLBresistin like beta−3.614Extracellular Spaceother24AMD1adenosylmethionine decarboxylase 1−3.515Cytoplasmenzyme25C1orf198chromosome 1 open reading frame 198−3.515Otherother26DGKIdiacylglycerol kinase, iota−3.515Cytoplasmkinase27DYNLT3dynein, light chain, Tctex-type 3−3.515Cytoplasmother28EPHA6EPH receptor A6−3.515Plasma Membranekinase29GABRA6gamma-aminobutyric acid (GABA) A receptor, alpha 6−3.515Plasma Membraneion channel30Gk2glycerol kinase 2−3.515Cytoplasmother31GLT1D1glycosyltransferase 1 domain containing 1−3.515Extracellular Spaceenzyme32HMGN2high mobility group nucleosomal binding domain 2−3.515Nucleusother33KLHL17kelch-like family member 17−3.515Cytoplasmother34Olfr266olfactory receptor 266−3.515Plasma MembraneG-protein coupled receptor35Ottovary testis transcribed−3.515Otherother36P2RX7purinergic receptor P2X, ligand-gated ion channel, 7−3.515Plasma Membraneion channel37PTERphosphotriesterase related−3.515Otherenzyme38Rnf213ring finger protein 213−3.515Cytoplasmenzyme39SERPINC1serpin peptidase inhibitor, clade C (antithrombin), member 1−3.515Extracellular Spaceenzyme40TPD52L1tumor protein D52-like 1−3.515Cytoplasmother41ZMAT4zinc finger, matrin-type 4−3.515Nucleusother42RBM20RNA binding motif protein 20−3.462Nucleusother43BEGAINbrain-enriched guanylate kinase-associated−3.408Nucleusother44CHSY3chondroitin sulfate synthase 3−3.408Cytoplasmenzyme45CKAP4cytoskeleton-associated protein 4−3.408Cytoplasmother46DPF3D4, zinc and double PHD fingers, family 3−3.408Otherother47Ear2eosinophil-associated, ribonuclease A family, member 2−3.408Cytoplasmenzyme48FAM135Bfamily with sequence similarity 135, member B−3.408Otherenzyme49POT1protection of telomeres 1−3.408Nucleusother50POU6F1POU class 6 homeobox 1−3.408Nucleustranscription regulatorFig. 2The 5 most significant biological functions and diseases related to changes in the methylation patterns. The number of molecules in the dataset associated with a known function was determined by IPA functional analysisTable 3Ingenuity Pathway Analysis of gene networksRankMolecules in networkScoreFocus moleculesTop function1↑AMOT,↑ANKRD26,↑CDKN1A,↓CEP152,↓CGGBP1,↓CPA3,↑CPVL, ↓DYNLL2, ↑EID2, ↓ELAC2, ↑EPB41L2, ↑EPB41L3, ↑FRMD6, ↑KIAA0195, ↑MAGEB1, ↑MBNL1, ↑MBNL2, ↑N4BP2L2, ↓NKD2, ↑NSA2, ↑RASSF4, ↓RASSF8, ↑RNF34, ↓SERPINI2, ↑SLC30A5, ↓SLC30A6, ↑SP110, ↑SP140, ↓SPAG5, ↑SYF2, ↓TROAP, ↑TXNDC11, ↑VGLL4, ↑WNT16, ↑WWC13035Cancer, Cell Cycle, Molecular Transport2↑ACACA, ↓ATRNL1, ↓BHMT, ↑CYP2A13, ↓Cyp2c70, ↑CYP3A43, ↓DCLRE1A, ↑E330013P04Rik, ↓FASN, ↑GPC6, ↑GSTP1, ↓HNMT, ↓IVNS1ABP, ↓Keg1, ↓Lcn4, ↑LRTM1, ↓MC4R, ↓Mill1, ↑MRGPRX3, ↑MT1E, ↑MTF1, ↑NR1H4, ↑RORA, ↑SLC13A1, ↑SLC16A7, ↓SLC29A4, ↓SLC30A1, ↓SLC38A4, ↑SULT1C3, ↓TMC6, ↓UCP1, ↑UPP2, ↓Xlr3c (includes others), ↑ZNF275, ↓ZNF2923035Renal Damage, Renal Tubule Injury, Molecular Transport3↑ABTB2, ↑ALKBH8, ↑ALPK1, ↓BCKDHB, ↑BTBD7, ↑C11orf70, ↑C20orf194, ↑CAMKV, ↓CCDC39, ↑CUL2, ↓CUL3, ↑DCLK2, ↑EGFLAM, ↑FAM98A, ↓FARS2, ↑FBXO10, ↑FBXO34, ↑G2E3, ↓G3BP2, ↑HSP90AA1, ↓KCNG1, ↓KCNS3, ↓KCTD8, ↑KLHL10, ↓KLHL14, ↑KLHL29, ↑KLHL32, ↑KLHL36, ↑KRR1, ↑QDPR, ↑RCBTB1, ↓SEPHS1, ↓UST, ↓YWHAE, ↑ZBED43035Hereditary Disorder, Respiratory Disease, Metabolic Disease4↓ABCA6, ↓ABLIM3, ↓ABRA, ↑AIF1L, ↓AMBRA1, ↓ARAP2, ↓ARL6, ↓ATL2, ↓CAPN5, ↑CAPN6, ↓CASP12,CD80/CD86, ↑CLEC2D, ↑CLEC6A, ↑CRTAM, ↑GBP5, ↑Gbp8,Gbp6 (includes others), ↑GFM1, ↑GIMAP1-GIMAP5, ↑Gvin1 (includes others), ↑HERC6, ↑IFNG, ↓KIAA0226, ↓KIF16B,↑KLRB1, ↓KMO, ↓KY, ↑LAMP3, ↑LIX1, ↓Neurl3, ↑PCDH17, ↑Phb, ↑PILRB, ↓PMP22834Endocrine System Disorders, Gastrointestinal Disease, Immunological Disease5↑AFF2, ↑AP4S1, ↑ASAP2, ↓C21orf91, ↑C2orf88, ↑DLGAP1, ↑Eif2s3x, ↓FAM110A, ↑GNS, ↑GRB2, ↑HDGFRP3, ↓KCNH7, ↓KIRREL, ↑KRT83, ↑LRFN4, ↑MEPE, ↑NCK1, ↑NCKAP5, ↓PANX2, ↑PHACTR2, ↑RALGAPA2, ↓RALGPS1, ↑SEPN1, ↑SH2D4A, ↑SHANK2, ↓SHROOM2, ↓SLCO2A1, ↑SNX8, ↑SNX12, ↑SNX18, ↓SPRY, ↑TJAP1, ↑TTYH2, ↑WDR44, ↑ZNF322834Cellular Assembly and Organization, Tissue Development, Cellular Function and Maintenance↑, increased methylation; ↓, decreased methylationFig. 3The most significant networks determined by IPA: cancer, cell cycle, and molecular transport. The IPA network analysis was conducted using the genes that were differentially methylated and their close relationships. IPA used triangle connectivity based on 30 focus genes and built the network according to the number of interactions between a single gene and others in the existing network. Red, increased methylation; green, decreased methylation

Canonical pathways associated with methylation changes in Apc mutant polyps were analyzed based on the ratio of the number of input genes to the total number of reference genes in the corresponding pathways in the IPA knowledge bases. Fisher's exact test was employed to calculate the P values to determine whether the associations between the differentially methylated genes and the canonical pathways were significant or random. Using a cutoff value of P \< 0.05, IPA identified 84 significant signaling pathways that contained genes with increased or decreased methylation. The 15 most significant pathways that correlated with methylation changes in polyps are presented in Fig. [4](#Fig4){ref-type="fig"}. Notably, regulation of the epithelial-mesenchymal transition (EMT) pathway was mapped by IPA and ranked as the 4th most significant canonical pathway associated with altered methylation. According to the IPA knowledge bases, the regulation of the EMT pathway includes 196 molecules. Among these molecules, 62 displayed greater than a 2 fold change (log~2~) in methylation in the polyps from Apc^min/+^ mice by MeDIP-seq. The abnormal methylation changes in the EMT pathway included alterations in the methylation profiles of kinases, peptidases, phosphatases, transcription regulators, transmembrane receptors, and microRNAs. Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} lists the genes involved in the EMT pathway that exhibited altered methylation (37 genes with increased methylation in Table [4](#Tab4){ref-type="table"}; 25 genes with decreased methylation in Table [5](#Tab5){ref-type="table"}). Signaling pathways, such as the Wnt/β-catenin, TGF-β, NOTCH, and receptor tyrosine kinase (RTK) pathways, can initiate an EMT program alone or in combination \[[@CR21]\]. Although the genes that were determined to have differential methylation patterns in polyps by MeDIP-seq were not significantly associated with the TGF-β, NOTCH, and RTK signaling pathways, the Wnt/β-catenin pathway was identified as one of the most significant canonical pathways implicated based on methylation changes in the polyps (ranked 11th). Specifically, 53 out of 175 molecules in this pathway showed methylation changes of greater than 2-fold (log~2~) in polyps from Apc^min/+^ mice; these molecules are listed in Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"} (30 genes with increased methylation in Table [6](#Tab6){ref-type="table"}; 23 genes with decreased methylation in Table [7](#Tab7){ref-type="table"}). Additionally, we found many shared genes in the EMT and Wnt/β-catenin pathways with altered methylation levels; these genes are shown in bold in Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}. To understand the role of DNA methylation in the crosstalk between the EMT and Wnt/β-catenin pathways in Apc^min/+^ mice, IPA was utilized to predict the direct interaction of the differentially methylated genes in these two pathways based on the publication database (Fig. [5](#Fig5){ref-type="fig"}). The pathway analysis of the MeDIP-seq data suggested that cellular changes mediated via the EMT and Wnt/β-catenin pathways may be significantly associated with altered DNA methylation in polyps from Apc^min/+^ mice.Fig. 4The 15 most significant canonical pathways related to changes in the methylation patterns. The left y-axis (bar graph) presents the data as the log (*p*-value) of each pathway using Fisher's exact test. The right y-axis (line graph) corresponds to the ratio data for each pathway. The ratios were calculated as the number of input molecules mapped to a specific pathway divided by the total number of molecules in the given pathwayTable 4Genes with increased methylation that mapped to the regulation of the EMT pathway by IPASymbolGene namelog~2~ Fold ChangeLocationType(s)SMAD3SMAD family member 33.877Nucleustranscription regulatorJAG1jagged 13.614Extracellular Spacegrowth factor**WNT5Awingless-type MMTV integration site family, member 5A3.292Extracellular Spacecytokine**FGF13fibroblast growth factor 133.100Extracellular Spacegrowth factor**WNT10Awingless-type MMTV integration site family, member 10A3.100Extracellular Spaceother**EGFRepidermal growth factor receptor2.877Plasma MembranekinaseFGF7fibroblast growth factor 72.877Extracellular Spacegrowth factorFGF14fibroblast growth factor 142.877Extracellular Spacegrowth factorID2inhibitor of DNA binding 2, dominant negative helix-loop-helix protein2.877Nucleustranscription regulatorPIK3C2Aphosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha2.877Cytoplasmkinase**FZD1frizzled class receptor 12.752Plasma MembraneG-protein coupled receptorCDH12cadherin 12, type 2 (N-cadherin 2)2.614Plasma Membraneother**FGF8fibroblast growth factor 8 (androgen-induced)2.614Extracellular Spacegrowth factor**FZD8frizzled class receptor 82.614Plasma MembraneG-protein coupled receptor**JAK2Janus kinase 22.614CytoplasmkinasePIK3C2Gphosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma2.614CytoplasmkinaseZEB1zinc finger E-box binding homeobox 12.614Nucleustranscription regulatorGSCgoosecoid homeobox2.462Nucleustranscription regulatorADAM17ADAM metallopeptidase domain 172.292Plasma MembranepeptidaseFGF9fibroblast growth factor 92.292Extracellular Spacegrowth factorFGF11fibroblast growth factor 112.292Extracellular Spacegrowth factorFGFR2fibroblast growth factor receptor 22.292Plasma MembranekinaseFRS2fibroblast growth factor receptor substrate 22.292Plasma MembraneotherGRB2growth factor receptor-bound protein 22.292CytoplasmotherLOXlysyl oxidase2.292Extracellular SpaceenzymeNCSTNnicastrin2.292Plasma MembranepeptidasePARD6Bpar-6 family cell polarity regulator beta2.292Plasma MembraneotherPIK3CGphosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma2.292CytoplasmkinasePIK3R1phosphoinositide-3-kinase, regulatory subunit 1 (alpha)2.292CytoplasmkinaseSOS2son of sevenless homolog 2 (Drosophila)2.292Cytoplasmother**TGFB2transforming growth factor, beta 22.292Extracellular Spacegrowth factorWNT2wingless-type MMTV integration site family member 22.292Extracellular Spacecytokine**METMET proto-oncogene, receptor tyrosine kinase2.180Plasma Membranekinase**AKT3v-akt murine thymoma viral oncogene homolog 32.100Cytoplasmkinase**TWIST2twist family bHLH transcription factor 22.100Nucleustranscription regulator**WNT2Bwingless-type MMTV integration site family, member 2B2.100Extracellular SpaceotherWNT16wingless-type MMTV integration site family, member 162.029Extracellular Spaceother**Table 5Genes with decreased methylation that mapped to the regulation of the EMT pathway by IPASymbolGene namelog~2~ Fold ChangeLocationType(s)PTPN11protein tyrosine phosphatase, non-receptor type 11−3.877CytoplasmphosphatasePDGFDplatelet derived growth factor D−3.167Extracellular Spacegrowth factorRRAS2related RAS viral (r-ras) oncogene homolog 2−3.090Plasma MembraneenzymeFGF10fibroblast growth factor 10−2.877Extracellular Spacegrowth factorFGF12fibroblast growth factor 12−2.877Extracellular Spaceother**CDH2cadherin 2, type 1, N-cadherin (neuronal)−2.708Plasma Membraneother**ETS1v-ets avian erythroblastosis virus E26 oncogene homolog 1−2.708Nucleustranscription regulatormir-155microRNA 155−2.708CytoplasmmicroRNAPIK3C3phosphatidylinositol 3-kinase, catalytic subunit type 3−2.708Cytoplasmgrowth factorPSEN2presenilin 2−2.708Cytoplasmpeptidase**TGFB3transforming growth factor, beta 3−2.708Extracellular Spacegrowth factor**SOS1son of sevenless homolog 1 (Drosophila)−2.515Cytoplasmother**WNT11wingless-type MMTV integration site family, member 11−2.515Extracellular Spaceother**SMAD4SMAD family member 4−2.292Nucleustranscription regulator**WNT7Awingless-type MMTV integration site family, member 7A−2.292Extracellular Spacecytokine**SMAD2SMAD family member 2−2.167Nucleustranscription regulator**TCF7L1transcription factor 7-like 1 (T-cell specific, HMG-box)−2.167Nucleustranscription regulator**CLDN3claudin 3−2.029Plasma Membranetransmembrane receptorGAB1GRB2-associated binding protein 1−2.029CytoplasmotherHMGA2\--−2.029OtherotherRAF1Raf-1 proto-oncogene, serine/threonine kinase−2.029Cytoplasmkinase**TCF7L2transcription factor 7-like 2 (T-cell specific, HMG-box)−2.029Nucleustranscription regulator**TWIST1twist family bHLH transcription factor 1−2.029Nucleustranscription regulator**WNT7Bwingless-type MMTV integration site family, member 7B−2.029Extracellular SpaceotherWNT8Bwingless-type MMTV integration site family, member 8B−2.029Extracellular Spaceother**Table 6Genes with increased methylation that mapped to the Wnt/β-catenin pathway by IPASymbolGene namelog~2~ Fold ChangeLocationType(s)SOX11SRY (sex determining region Y)-box 113.614Nucleustranscription regulatorTLE1transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)3.462Nucleustranscription regulatorSOX2SRY (sex determining region Y)-box 23.292Nucleustranscription regulator**WNT5Awingless-type MMTV integration site family, member 5A3.292Extracellular SpacecytokineWNT10Awingless-type MMTV integration site family, member 10A3.100Extracellular Spaceother**CDH5cadherin 5, type 2 (vascular endothelium)2.877Plasma MembraneotherDKK3dickkopf WNT signaling pathway inhibitor 32.877Extracellular SpacecytokineHDAC1histone deacetylase 12.877Nucleustranscription regulatorPPP2R3Aprotein phosphatase 2, regulatory subunit B", alpha2.877NucleusphosphataseRUVBL2RuvB-like AAA ATPase 22.877Nucleustranscription regulatorUBDubiquitin D2.877Nucleusother**FZD1frizzled class receptor 12.752Plasma MembraneG-protein coupled receptorCDH12cadherin 12, type 2 (N-cadherin 2)2.614Plasma MembraneotherFZD8frizzled class receptor 82.614Plasma MembraneG-protein coupled receptor**MYCv-myc avian myelocytomatosis viral oncogene homolog2.614Nucleustranscription regulatorSOX4SRY (sex determining region Y)-box 42.614Nucleustranscription regulatorSOX6SRY (sex determining region Y)-box 62.614Nucleustranscription regulatorAPC2adenomatosis polyposis coli 22.292CytoplasmenzymeAPPL2adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 22.292CytoplasmotherCSNK2A1casein kinase 2, alpha 1 polypeptide2.292CytoplasmkinaseMMP7matrix metallopeptidase 7 (matrilysin, uterine)2.292Extracellular SpacepeptidaseNR5A2nuclear receptor subfamily 5, group A, member 22.292Nucleusligand-dependent nuclear receptorPIN1peptidylprolyl cis/trans isomerase, NIMA-interacting 12.292NucleusenzymeTGFB2transforming growth factor, beta 22.292Extracellular Spacegrowth factor**WNT2wingless-type MMTV integration site family member 22.292Extracellular SpacecytokineAKT3v-akt murine thymoma viral oncogene homolog 32.100Cytoplasmkinase**FRAT1frequently rearranged in advanced T-cell lymphomas2.100Cytoplasmother**WNT2Bwingless-type MMTV integration site family, member 2B2.100Extracellular SpaceotherWNT16wingless-type MMTV integration site family, member 162.029Extracellular Spaceother**Table 7Genes with decreased methylation that mapped to the Wnt/β-catenin pathway by IPASymbolGene namelog~2~ Fold ChangeLocationType(s)ACVR1Cactivin A receptor, type IC−3.029Plasma MembranekinaseGNAQguanine nucleotide binding protein (G protein), q polypeptide−2.877Plasma MembraneenzymeSOX13SRY (sex determining region Y)-box 13−2.877Nucleustranscription regulatorWIF1WNT inhibitory factor 1−2.877Extracellular Spaceother**CDH2cadherin 2, type 1, N-cadherin (neuronal)−2.708Plasma Membraneother**PPP2R2Aprotein phosphatase 2, regulatory subunit B, alpha−2.708Cytoplasmphosphatase**TGFB3transforming growth factor, beta 3−2.708Extracellular Spacegrowth factor**PPP2R1Bprotein phosphatase 2, regulatory subunit A, beta−2.614Plasma MembranephosphataseCSNK1G3casein kinase 1, gamma 3−2.515Cytoplasmkinase**WNT11wingless-type MMTV integration site family, member 11−2.515Extracellular Spaceother**MARK2MAP/microtubule affinity-regulating kinase 2−2.292Cytoplasmkinase**WNT7Awingless-type MMTV integration site family, member 7A−2.292Extracellular SpacecytokineTCF7L1transcription factor 7-like 1 (T-cell specific, HMG-box)−2.167Nucleustranscription regulator**GJA1gap junction protein, alpha 1, 43 kDa−2.029Plasma MembranetransporterPPP2R2Bprotein phosphatase 2, regulatory subunit B, beta−2.029CytoplasmphosphatasePPP2R5Aprotein phosphatase 2, regulatory subunit B', alpha−2.029CytoplasmphosphataseSFRP2secreted frizzled-related protein 2−2.029Plasma Membranetransmembrane receptorSOX7SRY (sex determining region Y)-box 7−2.029Nucleustranscription regulatorSOX14SRY (sex determining region Y)-box 14−2.029Nucleustranscription regulator**TCF7L2transcription factor 7-like 2 (T-cell specific, HMG-box)−2.029Nucleustranscription regulator**TLE3transducin-like enhancer of split 3−2.029Nucleusother**WNT7Bwingless-type MMTV integration site family, member 7B−2.029Extracellular SpaceotherWNT8Bwingless-type MMTV integration site family, member 8B−2.029Extracellular Spaceother**Fig. 5Predicted interactions between molecules with altered methylation that mapped to the EMT and Wnt/β-catenin pathways. IPA predicted direct interaction of the genes with altered methylation patterns in the EMT and Wnt/β-catenin pathways based on the publication database. Red, increased methylation; green, decreased methylation

Discussion {#Sec5}
==========

Global hypomethylation and hypermethylation of CpG islands in tumor suppressor genes occurs in human colon cancer cell lines and primary colon adenomatous tissues \[[@CR12]\]. However, the global genomic distribution of aberrant methylation and the association of these methylation signatures with pivotal signaling pathways and biological networks in colon cancer remain unclear, mainly due to the limitations of the existing techniques for analyzing DNA methylation at specific sequences \[[@CR22]\]. Recently, the development of the MeDIP-based approach has enabled the rapid and comprehensive identification of multiple CpG sites. MeDIP in conjunction with high-throughput sequence (MeDIP-seq) provides a genome-wide mapping technique that has been successfully used to profile the global DNA methylation patterns of many cancer models \[[@CR23]--[@CR26]\]. Notably, Grimm et al. used MeDIP-seq to identify a large number of DMRs with distinct methylation patterns in Apc mutant adenomas, which are partially conserved between intestinal adenomas in Apc^min/+^ mice and human colon cancer \[[@CR27]\]. In the present study, we used pathway analysis after MeDIP-seq to screen the global genomic methylation profile to identify genomic loci with aberrant methylation patterns in adenomatous polyps from Apc^min/+^ mice and to determine the biological function, networks, and canonical pathways that were affected by the DNA methylation in Apc mutant adenomas.

The top-ranked genes with increased and decreased methylation may provide information to facilitate the discovery of key genes, therapeutic targets, and biomarkers for the development, diagnosis, prognosis, and prevention of colon cancer. For example, CTNNBL1 \[catenin (cadherin-associated protein) b-like 1\] exhibited increased methylation in adenomatous polyp tissue (log~2~ fold change = 4.1, Table [1](#Tab1){ref-type="table"}), as evidenced by MeDIP-seq. The CTNNBL1 gene is associated with obesity, a known risk factor for the development of CRC \[[@CR28]\]. Recently, CTNNBL1 was reported to be a putative regulator of the canonical Wnt signaling pathway, and mutations in and dysregulation of this pathway are involved in CRC \[[@CR29]\]. However, the potential epigenetic regulation of CTNNBL1 in colon cancer remains to be elucidated. To the best of our knowledge, this is the first report to suggest that CTNNBL1 might by aberrantly methylated in Apc mutant mice. Further experiments are necessary to investigate the epigenetic regulation of CTNNBL1 in colon cancer cells and patient specimens. CDKN1A (cyclin-dependent kinase inhibitor 1A, p21) showed increased methylation (log~2~ fold change = 3.6, Table [1](#Tab1){ref-type="table"}) in adenomatous polyp tissue compared with control tissue. CDKN1A is a cyclin-dependent kinase inhibitor that plays a key role in regulating the cell cycle, especially the G1/S checkpoint, and its expression is lost in most cases of colon cancer. By analyzing 737 CRC samples, Ogino et al. concluded that the down-regulation of p21 inversely correlates with microsatellite instability and the CpG island methylator phenotype in colon cancer \[[@CR30]\]. Here, we provided additional evidence by demonstrating potentially increased p21 methylation in Apc^min/+^ polyps.

It is commonly believed that promoter hypermethylation is associated with silencing of tumor suppressor genes in carcinogenesis \[[@CR31]\]. One study observed a significant increase in DNA methylation in primary colon adenocarcinoma samples relative to normal colon tissue by analyzing the DNA methylation data from Cancer Genome Atlas (TCGA) and found an inverse correlation between DNA methylation and gene expression: genes with cancer-specific DNA methylation showed decreased transcription activity in colon adenocarcinoma \[[@CR32]\]. However, Grimm et al. reported that the correlation of gene expression and DNA methylation applies only to a small set of genes by analyzing the results from MeDIP-seq and RNA-seq in normal intestine tissues and Apc mutant adenomas. In addition, they analyzed the mRNA expression of 31 selected tumor suppressors, only 2 were found both promoter hypermethylated and transcriptionally silenced. Surprisingly, the majority of tumor suppressors examined in their study did not exhibit a decreased transcriptional activity in adenoma compared to normal intestine samples \[[@CR27]\]. These results suggested that silencing of tumor suppressor genes by aberrant methylation may not be common events during early polyposis of Apc mutant mice. Nevertheless, it is possible that epigenetic changes mediated gene silencing arises during progression of adenoma to carcinoma \[[@CR33]\]. Furthermore, it was reported that instead of directly intervene active promoters, DNA methylation affects genes that are already silent by other mechanisms such as histone modifications \[[@CR34]\]. Thus, further studies are needed to elucidate the dynamic changes of DNA methylation, histone modifications, and gene transcription in different stages, such as initiation, progression, and metastasis during colon carcinogenesis.

This study aimed to discover functions and pathways associated with epigenomic alterations in colon cancer in addition to the individual affected molecules. We utilized IPA to interpret the MeDIP-seq data in the context of molecular interactions, networks, and canonical pathways. IPA revealed that the genes with altered methylation patterns in adenomatous tissues predominantly occupied the cancer and cell cycle networks (Table [3](#Tab3){ref-type="table"}) and the cancer and gastrointestinal disease functional categories (Fig. [2](#Fig2){ref-type="fig"}). This information suggested that dynamic epigenetic modifications might occur in genes associated with cancer, cell cycle regulation, and gut disease development in Apc^min/+^ mice.

Biological changes that lead to the switch from an epithelial to a mesenchymal cell phenotype, defined as EMT, play an important role in embryonic development and carcinogenesis \[[@CR35]\]. In the context of tumorigenesis-associated EMT, neoplastic cells lose epithelial characteristics, such as cell-cell adhesion, cell polarity, and lack of motility, and acquire mesenchymal features, such as migratory ability, invasiveness, plasticity, and resistance to apoptosis \[[@CR21]\]. The morphological alterations that occur during EMT enable neoplastic cells to escape from the basement membrane, migrate to neighboring lymph nodes, and eventually enter the circulation to establish secondary colonies at distant sites \[[@CR36]\]. Thus, EMT program activation is considered a critical step in tumor growth, angiogenesis, and metastasis \[[@CR37]\]. Chen et al. reported elevated expression of the mesenchymal marker vimentin in intestinal adenomas from Apc^min/+^ mice and suggested that molecular alterations in the initial steps of EMT are involved in early tumorigenesis in Apc^min/+^ mice; the early stages of intestinal tumorigenesis lack signs of invasion and metastasis \[[@CR38]\]. These interesting observations highlighted the necessity to study the EMT process during early tumorigenesis. Although the molecular and biochemical mechanisms involved in the initiation and regulation of EMT in carcinogenesis are not yet fully understood, they appear to be associated with growth factor receptors (for example, RTKs), signaling pathways (for example, the Wnt/β-catenin, NOTCH, and TGF-β pathways), and stimuli (for example, oxidative stress) \[[@CR39]\]. The involvement of epigenetic events in regulating the EMT proteome during carcinogenesis was recently demonstrated \[[@CR40]\]. Using ChIP-seq (chromatin immunoprecipitation followed by sequencing) assays, Cieslik et al. showed that EMT is driven by the chromatin-mediated activation of transcription factors \[[@CR41]\]. The current study identified many genes with increased or decreased methylation in the EMT pathway (Fig. [3](#Fig3){ref-type="fig"}, Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}), suggesting that aberrant DNA methylation may be associated with the activation of EMT during tissue remodeling in early tumorigenesis in Apc^min/+^ mice. The present study also provided useful information regarding important molecules in the EMT pathway that undergo alterations in their methylation pattern during polyposis in Apc^min/+^ mice. For example, SMAD3 (mothers against decapentaplegic homolog 3), a molecule that plays an essential role in TGF-β pathway-mediated EMT, was one of the genes that exhibited increased methylation (log~2~ fold change = 3.9, Table [4](#Tab4){ref-type="table"}) in adenomas in Apc^min/+^ mice. Interestingly, SMAD3 deficiency promotes tumor formation in the distal colon of Apc^min/+^ mice \[[@CR42]\]. EGFR (epidermal growth factor receptor), another important molecule that exhibited increased methylation, has been implicated in EMT in adenomas (log~2~ fold change = 2.9, Table [4](#Tab4){ref-type="table"}). EGFR can induce EMT in cancer cells by up-regulating Twist \[[@CR43]\], and promoter methylation of EGFR has been detected in metastatic tumors from patients with CRC \[[@CR44]\]. The results of the current study indicated that aberrant methylation of EGFR may occur during early tumorigenesis in Apc^min/+^ mice. Important transcription factors in the EMT pathway, including ZEB 1 and TWIST 2, also exhibited increased methylation in adenomas from Apc^min/+^ mice (Table [4](#Tab4){ref-type="table"}). Although the contribution of TWIST 2 to promoting EMT in breast cancer progression was recently reported \[[@CR45]\], there is limited knowledge of the role of TWIST 2 in colon cancer; however, one study proposed that TWIST 2 is a potential prognostic biomarker for colon cancer \[[@CR46]\]. Notably, aberrant methylation of TWIST 2 has been demonstrated in chronic lymphocytic leukemia \[[@CR47]\] and acute lymphoblastic leukemia \[[@CR48]\]. The present study is the first to suggest that methylation of the TWIST 2 gene may be involved in tumorigenesis in Apc^min/+^ mice. Further studies are necessary to elucidate the role of DNA methylation in EMT pathway regulation in early tumorigenesis in Apc^min/+^ mice.

Apc^min/+^ mice are thought to have a hyperactive Wnt/β-catenin pathway \[[@CR10]\], but the epigenetic modifications of the Wnt/β-catenin pathway are still not fully understood. IPA identified the Wnt/β-catenin pathway as one of the most significant canonical pathways that contained genes with increased or decreased methylation, suggesting an important role for epigenetic alterations in the Wnt/β-catenin pathway in tumorigenesis. Some of the molecules with increased or decreased methylation patterns that were mapped to this pathway in the present study are consistent with the findings of previous publications. For example, Dhir et al. analyzed tissue samples from inflammatory bowel disease (IBD) and colon cancer patients and demonstrated that aberrant methylation of Wnt/β-catenin signaling genes is an early event in IBD-associated colon cancer. Aberrant methylation of APC2 (adenomatousis polyposis coli 2), SFRP1 (secreted frizzled-related protein 1), and SFRP2 (secreted frizzled-related protein 2) is associated with the progression from colitis to neoplasia \[[@CR49]\]. In the current study, we observed increased methylation of APC2 and decreased methylation of SFRP2 in adenomas in Apc^min/+^ mice (Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}). Wang et al. demonstrated that black raspberries can prevent colonic ulceration in a DSS-induced model and in interleukin-10 knockout mice by epigenetically modifying genes with hypermethylated promoters in the Wnt/β-catenin pathway, such as DKK3 (dickkopf-related protein 3), APC, SFRP1, and SOX17 \[SRY (sex determining region Y)-box 17\] \[[@CR50], [@CR51]\]. In the present study, DKK3 consistently displayed increased methylation (log~2~ fold change = 2.9, Table [6](#Tab6){ref-type="table"}) in adenomas from Apc^min/+^ mice compared with normal tissue. Furthermore, we provided additional information regarding the genes with altered methylation in the Wnt/β-catenin pathway in polyps from Apc^min/+^ mice, potentially facilitating future research on the involvement of aberrantly methylated Wnt/β-catenin pathway components in colon cancer development and on potential targets for epigenetic modification for the prevention of colon cancer. Intestinal adenoma in mouse originated from intestinal stem cells (ISC), a small fraction of cells in proliferative crypts \[[@CR52]\]. Interestingly, Grimm and co-workers demonstrated that the adenoma-specific methylation signatures are not acquired from ISC by showing that the methylation patterns were similar in ISC, proliferative crypt cells, and differentiated villus cells, but are distinct in adenoma tissue \[[@CR27]\]. Since ISC are responsive to Wnt signaling and we identified Wnt/β-catenin pathway as one of the most significant pathways associated with DNA methylation in polyps from Apc^min/+^ mice, it would be important to understand the mechanisms underlying the acquisition of aberrant DNA methylation patterns in Wnt/β-catenin pathway in adenoma and how the hypermethylated genes involved in Wnt/β-catenin pathway influence the neoplastic transformation from ISC to adenoma. Furthermore, the Wnt/β-catenin pathway is intimately associated with EMT pathway \[[@CR53]\]. The present study provided valuable information regarding the potential crosstalk between the EMT and Wnt/β-catenin pathways, which are both affected by DNA methylation in Apc^min/+^ mice (Fig. [5](#Fig5){ref-type="fig"}). Further studies are needed to understand the role of the complex crosstalk between multiple signaling pathways in the progression of colon cancer.

In addition to DNA methylation, histone modification and non-coding RNA are major epigenetic mechanisms that regulate gene transcription in carcinogenesis \[[@CR54]\]. It is currently accepted that these epigenetic modifications are linked to one another in the modulation of the epigenome landscape \[[@CR55], [@CR56]\]. For example, these epigenetic modifications may work in combination in carcinogenesis \[[@CR57]\]. It was found that DNA hypermethylation in Apc mutant adenomas preferentially target the polycomb repressive complex 1/2 (PRC 1/2) target genes, suggesting an interplay of DNA methylation and histone modification in Apc^min/+^ mice \[[@CR27]\]. On the other hand, different epigenetic mechanisms may cross-regulate each other in the regulation of cellular activity. For instance, the expression of certain microRNAs is potentially controlled by DNA methylation or histone modification. However, some microRNAs can target epigenetic-modifying enzymes, such as DNMTs (DNA methyltransferases) and EZH2 (enhancer of zeste homolog 2) \[[@CR58]\]. Furthermore, Tahara, et al. found that 74 chromatin regulatory genes are mutated more frequently in CpG island methylator phenotype - high CRC in the TCGA dataset \[[@CR59]\]. Changes in the methylation patterns of several genes encoding microRNAs, histone modification enzymes, and proteins that function in chromatin remodeling were identified using MeDIP-seq. For example, we discovered decreased methylation of microRNA-155 (log~2~ fold change = −2.7, Table [5](#Tab5){ref-type="table"}), which mapped to the EMT pathway; microRNA-155 expression promotes the migration and invasion of several CRC cell lines \[[@CR60]\]. Moreover, HDAC1 (histone deacetylase 1) was mapped to the Wnt/β-catenin pathway with a 2.9-fold (log~2~) increase in methylation in Apc mutant polyps (Table [6](#Tab6){ref-type="table"}). In addition, we observed an increased methylation in the gene coding for chromodomain-helicase-DNA-binding protein 1 (CHD1) in Apc mutant polyps (data not shown). CHD1 protein is known to be involved in transcription-related chromatin remodeling \[[@CR61]\]. Taken together, our data indicated that epigenetic alterations may be complex and may occur at multiple levels during tumorigenesis in Apc^min/+^ mice.

Conclusions {#Sec6}
===========

In conclusion, polyps from Apc^min/+^ mice exhibited extensive, aberrant DNA methylation. The methylation changes in the genes detected using the MeDIP-seq assay were mainly attributed to functions and networks in cancer, the cell cycle, and gastrointestinal diseases. These differentially methylated genes were situated in several canonical pathways that are important in colon cancer, such as the EMT and Wnt/β-catenin signaling pathways.

Materials and methods {#Sec7}
=====================

Mouse strains {#Sec8}
-------------

C57BL/6 J male mice that are heterozygous for the Apc allele (Apc^min/+^) and their wild type littermates (Apc^+/+^) were originally obtained from Jackson Laboratories (Bar Harbor, ME, USA). The animals were housed in the Animal Care Facility at Rutgers University with a 12 h-light/12 h-dark cycle and were provided ad libitum access to food and water. The Apc^min/+^ and control mice were sacrificed by CO~2~ inhalation at 20 weeks of age. Polyp and intestine samples were collected as previously described \[[@CR62]\]. Briefly, after sacrificing the mice, the gastrointestinal tract was removed, opened longitudinally, and rinsed thoroughly with saline. Intestinal adenomatous polyps were excised from the intestines carefully. The normal intestine tissue and polyps were snap frozen and stored at −80 °C for future use.

DNA extraction {#Sec9}
--------------

Genomic DNA was isolated from adenomatous polyps from three Apc^min/+^ mice and from normal intestinal tissue from three Apc^+/+^ littermates using a DNeasy Kit (Qiagen, Valencia, CA, USA). Prior to fragmentation by Covaris (Covaris, Inc., Woburn, MA, USA), the quality of the extracted genomic DNA was confirmed by agarose gel electrophoresis and OD ratio. After fragmentation, the genomic DNA was further assessed for size distribution using an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The fragmented genomic DNA concentrations were measured with a Nanodrop spectrophotometer.

MeDIP-seq {#Sec10}
---------

MeDIP was performed using a MagMedIP kit (Diagenode, Denville, NJ, USA) as previously described \[[@CR63]\]. Briefly, immunoprecipitations were performed using a monoclonal antibody against 5-methylcytidine (Diagenode, Denville, NJ, USA) to separate the methylated DNA fragments from the unmethylated fragments. The captured DNA was used to create the Illumina libraries using NEBNext reagents (catalog\# E6040; New England Biolabs, Ipswich, MA, USA). After the quality of the libraries was evaluated, the samples were sequenced using an Illumina HiSeq 2000 machine. The results were analyzed for data quality and exon coverage using the platform provided by DNAnexus (DNAnexus, Inc., Mountain View, CA, USA). Subsequently, the samples were subjected to Illumina next-generation sequencing (Otogenetics Corporation, Norcross, GA, USA). After downloading the BAM files for analysis, MeDIP alignments were compared with control samples using Cuffdiff 2.0.2 as previously described \[[@CR64], [@CR63]\]. To judge the quantitative enrichment in MeDIP samples versus control samples in Cuffdiff, the overlapping regions of sequence alignment common to the MeDIP and control samples were used. Significant peaks at a 5 % false discovery rate (FDR) with a minimum of a 4-fold difference in R (Cummerbund package) were selected. The peaks were matched with adjacent annotated genes using ChIPpeakAnno as previously described \[[@CR65]\].

Ingenuity Pathway Analysis (IPA) {#Sec11}
--------------------------------

To investigate the significance of the altered methylation observed by MeDIP-seq, we analyzed genes that exhibited greater than a 2-fold change (log~2~) in methylation (Apc^min/+^ polyps vs. control) using IPA (IPA 4.0, Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com)). IPA utilized gene symbols that were identified as neighboring enriched methylation peaks by ChIPpeakAnno for all of the analyses. IPA mapped the input genes to its knowledge bases and identified the most relevant biological functions, networks, and canonical pathways related to the altered methylation profiles in the Apc mutant polyps.
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